Industry Symposium 12 【Bayer】

This session will delve into the evolving treatment landscape for advanced prostate cancer, with a strong emphasis on the integration of real-world evidence and patient-specific factors into therapy selection. A key focus will be placed on current intensification strategies for both metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC)—including the use of chemotherapy, novel hormonal agents, radiopharmaceutical therapies, and more.

Regional variations in treatment practices will also be explored to better understand how local experiences influence clinical decisions—particularly in the management of mHSPC.

Through interactive dialogue, experts will share practical insights and diverse perspectives on optimizing therapy management and improving patient outcomes across a range of clinical settings.